Cancer survival in Hebei Province jumps nearly 20 points in a decade, population study finds

A sweeping population-based analysis of more than 139,000 cancer patients in Hebei Province, China, has documented one of the fastest recorded improvements in cancer survival anywhere in the country, with five-year age-standardized relative survival climbing from 40.2 percent to 59.9 percent between 2009 and 2018. The study, published in BMC Public Health by researchers at the Cancer Research Institute in Hebei Province and Hebei Medical University, pooled records from 13 population-based cancer registries and followed patients diagnosed during the decade up to 31 December 2025, offering an unusually long observational window for measuring real-world cancer-control progress.

The headline figure conceals a starkly uneven landscape. Overall five-year age-standardized relative survival across all cancers combined stood at 47.7 percent, but individual cancer types ranged from 89.3 percent for thyroid cancer down to 13.0 percent for pancreatic cancer. Uterine cancer at 78.8 percent, breast cancer at 77.6 percent, testicular cancer at 76.2 percent, cervical cancer at 70.1 percent and bladder cancer at 69.4 percent rounded out the most survivable diagnoses. At the opposite end of the spectrum, liver cancer at 18.6 percent, lung cancer at 30.4 percent, gallbladder cancer at 36.4 percent and esophageal cancer at 37.0 percent remained among the deadliest, reflecting the persistent challenge posed by cancers of the digestive and respiratory systems, which dominate China’s cancer burden.

Relative survival, the metric at the heart of the study, is a technical but powerful indicator. It compares the observed survival of cancer patients with the survival expected in a comparable group of the general population matched for age, sex and calendar year, thereby isolating the excess mortality attributable to the cancer itself while remaining robust to incomplete cause-of-death information. Age-standardization using the International Cancer Survival Standard weights allows fair comparison across populations with different age structures, a critical consideration in a province where the population is aging rapidly and older patients carry a disproportionate share of diagnoses.

The gender gap in the data is striking. Women in Hebei recorded five-year age-standardized relative survival of 55.7 percent, compared with just 40.8 percent for men, a difference of nearly 15 percentage points. Part of the explanation lies in the composition of cancer types: women are more likely to be diagnosed with relatively survivable cancers such as thyroid, breast and uterine malignancies, while men face higher rates of liver, lung and esophageal cancers with poor prognosis. Behavioral risk factors, including substantially higher rates of smoking and alcohol consumption among Chinese men, further widen the survival divide by driving diagnoses of the least survivable cancers.

Age emerged as the other powerful determinant of outcome. Relative survival fell monotonically from 67.8 percent among patients aged 44 years or younger to 33.0 percent among those aged 75 years or older. The pattern reflects both biology and health-system dynamics: younger patients tend to be diagnosed with more treatable cancers, tolerate aggressive surgery and chemotherapy better, and are more likely to be detected through screening programs. Older patients, by contrast, often present with advanced disease, have more comorbidities that complicate treatment, and may be under-referred for definitive therapy, a phenomenon documented in many health systems and particularly relevant in rural parts of Hebei where access to tertiary cancer centers remains limited.

The temporal trend is the study’s most consequential finding. Using Joinpoint regression, a statistical technique that fits consecutive linear segments on a logarithmic scale to identify years in which trends change direction, the researchers calculated an annual average percent change of 3.14 percent for overall survival across the decade, with a 95 percent confidence interval of 0.28 to 8.75 percent. The improvement of 19.7 percentage points over ten years far exceeds what is typically reported in high-income countries over comparable periods, suggesting that Hebei’s investments in early detection, treatment capacity and cancer registration have translated into measurable gains in patient outcomes.

Behind the overall trend, specific cancers drove the decade’s progress. Liver cancer survival improved with an annual average percent change of 6.53 percent, laryngeal cancer by 4.50 percent, gallbladder cancer by 4.20 percent, leukemia by 4.06 percent and esophageal cancer by 3.96 percent. The improvement in liver and esophageal cancers is particularly meaningful because these malignancies are endemic in parts of northern China, with high incidence historically linked to viral hepatitis, aflatoxin exposure, alcohol and dietary factors. Rising survival in these cancers likely reflects a combination of hepatitis B vaccination programs rolled out nationally since the 1990s, expanded screening in high-risk areas, improved imaging and surgical techniques, and wider adoption of antiviral therapy and targeted agents.

The study’s methodology deserves attention for what it reveals about data quality in population-based cancer research. The cohort approach computes survival for all patients diagnosed in a given period, providing a direct measure of the experience of real patients rather than model-based projections. The inclusion of 139,293 first primary invasive cancers from 13 registries, with follow-up extending more than seven years beyond the end of the diagnosis period, minimizes the bias that shorter follow-up windows introduce. Quality indicators standard in cancer registry research, such as the proportion of cases morphologically verified and the proportion identified only through death certificates, help gauge whether apparent survival gains reflect genuine improvement or artifacts of better case ascertainment over time.

For policymakers, the findings carry a dual message. Hebei has made substantial progress in improving cancer survival, consolidating achievements that align with national cancer-control plans emphasizing early detection, standardized diagnosis and treatment, and improved access to care. Yet the persistence of wide disparities across gender, age groups and cancer types signals that the benefits of progress have not been evenly distributed. The authors argue that sustained, targeted interventions remain critically important to consolidate existing achievements and advance equity in cancer prevention and control across the province, with particular attention needed for older patients, men, and cancers of the pancreas, liver and lung, where survival remains grim.

The Hebei data also contribute to a broader scientific conversation about cancer survival in low- and middle-income settings. Population-based survival statistics are the key indicator for evaluating cancer-control effectiveness precisely because they capture the experience of every diagnosed patient in a defined population, not just those treated at elite centers. As China’s population ages and cancer incidence continues to rise, the trajectory documented in Hebei between 2009 and 2018 offers a template for what coordinated investment in registration, screening and treatment can achieve, while the stubborn survival gap between the youngest and oldest patients serves as a reminder that demographic aging will test the durability of these gains in the decades ahead.

Subject of Research: Cancer survival

Article Title: Cancer survival in Hebei Province, China (2009–2018): a population-based study

Article References: Liu, Y., Li, D., Wu, S., Liu, B., He, Z., Nie, Y., & He, Y. (2026). Cancer survival in Hebei Province, China (2009–2018): a population-based study. BMC Public Health. https://doi.org/10.1186/s12889-026-29903-8

Image Credits: AI Generated

DOI: 10.1186/s12889-026-29903-8

Keywords: cancer survival, Hebei Province, population-based study, relative survival, BMC Public Health, China, cancer registry, Cancer, survival, Hebei, Province, population-based